Inhibition of Interleukin-8/C-X-C Chemokine Receptor 2 Signaling Axis Prevents Tumor Growth and Metastasis in Triple-Negative Breast Cancer Cells

PHARMACOLOGY · Published 2025-04-04 · DOI 10.1159/000545659

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1159/000545659

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• The therapy-induced senescence-associated secretory phenotype and epithelial-mesenchymal transition Axis in ovarian cancer: molecular mechanisms and therapeutic opportunities · Expert Opinion on Therapeutic Targets · 2026 · Cites or is cited by this article
• The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy · Frontiers in Immunology · 2026 · Cites or is cited by this article
• Nephroprotective Effects of Curcumin in Murine Models of Focal and Segmental Glomerulosclerosis · PHARMACOLOGY · 2025 · Same journal
• The Stability of Drugs Commonly Used in Intensive Care Units Co-Administered via Feeding Tube and Its Dependence on pH: An in vitro Study · PHARMACOLOGY · 2025 · Same journal
• Estrogen Receptors and Platelet-Activating Acetylhydrolase Activity in the Pathogenesis of Systemic Lupus Erythematosus · PHARMACOLOGY · 2025 · Same journal
• 3-Hydroxybutyrate Prevents Pulmonary Vein Arrhythmogenesis by Regulating Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Oxidative Stress · PHARMACOLOGY · 2026 · Same journal
• Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study · PHARMACOLOGY · 2024 · Same journal
• Phytochemicals as Emerging Antiproliferative Agents in Head and Neck Cancer: Molecular Mechanisms and Therapeutic Strategies · PHARMACOLOGY · 2025 · Same journal
• Expression of Concern · PHARMACOLOGY · 2024 · Same journal
• The Effects and Mechanisms of Indole Derivatives in Improving Doxorubicin-Induced Cardiomyopathy · PHARMACOLOGY · 2025 · Same journal